TITLE:
SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma

CONDITION:
Carcinoma, Renal Cell

INTERVENTION:
Interferon-alfa

SUMMARY:

      The purpose of this study is to test whether SU011248 has activity and is safe compared to
      interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma
      (RCC).
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Histologically confirmed renal cell carcinoma of clear cell histology with metastases

          -  Evidence of measurable disease by radiographic technique

          -  Eastern Cooperative Oncology Group [ECOG] performance status of 0 or 1

        Exclusion Criteria:

          -  Prior systemic (including adjuvant or neoadjuvant) therapy of any kind for RCC

          -  History of or known brain metastases

          -  Serious acute or chronic illness or recent history of significant cardiac abnormality
      
